Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025International Journal of Molecular SciencesOpen Access

Real-World Impact of Finerenone on Albuminuria in Patients with Diabetes and CKD

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJorge Iván Zamora-CarrilloMPMarc Patricio-Liébana

Discussion

Loading...

Member takes

Overview

Real-world evidence shows finerenone treatment results in a significant reduction of albuminuria in patients with chronic kidney disease and diabetes, indicating its potential benefits.

Key Points

  • Albuminuria decreased by 37.1% after 6 months of finerenone treatment, with significant reductions noted in patients with initial eGFR drops.
  • Patients with diabetes and chronic kidney disease involved in this cohort study experienced stable eGFR after an initial decline of 9.5%.
  • Clinical data were assessed at baseline and at 1, 3, and 6 months to evaluate treatment outcomes.
  • Finerenone was well tolerated, despite reported hyperkalemia in 18.3% of participants and discontinuation due to adverse events in 10%.

Cite This Study

Zamora-Carrillo et al. (2025) studied this question.

synapsesocial.com/papers/6930dc81ea1aef094cca25d2https://doi.org/10.3390/ijms262311584
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Finerenone in diabetic kidney disease: Findings from a single-center retrospective observational study2026
  2. 2Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China2025
  3. 3Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease2025
  4. 4Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD2025 · 7 citations
  5. 5Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study2025